BMY Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
19 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 10.33
- PEG ratio
- 1.69
- P/B
- 5.98
- P/S (TTM)
- 2.71
- EV/EBITDA
- 9.95
Profitability & growth
- ROE (TTM)
- 46.6%
- Operating margin
- 34.4%
- Revenue growth YoY
- 5.7%
- Dividend yield
- 3.9%
- Beta
- 0.23
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Bristol-Myers Squibb Company
Company profileBristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- ROUTE 206 & PROVINCE LINE ROAD, PRINCETON, NJ
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
